The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke
Abstract
:1. Introduction
2. The Risk Factors for Developing Stroke
3. Inflammation in Stroke
4. Resolvins: Synthesis
5. Receptors for Resolvins
6. The Role of Resolvins in Stroke
7. Conclusions
8. Method of Article Search
Author Contributions
Funding
Conflicts of Interest
References
- Guzik, A.; Bushnell, C. Stroke epidemiology and risk factor management. Continuum (Minneap. Min.) 2017, 23, 15–39. [Google Scholar] [CrossRef] [PubMed]
- Bejot, Y.; Bailly, H.; Durier, J.; Giroud, M. Epidemiology of stroke in Europe and trends for the 21st century. La Presse Med. 2016, 45, e391–e398. [Google Scholar] [CrossRef] [PubMed]
- Ramírez-Moreno, J.M.; Muñoz-Vega, P.; Alberca, S.B.; Peral-Pacheco, D. Health-related quality of life and fatigue after transient ischemic attack and minor stroke. J. Stroke Cerebrovasc. Dis. 2019, 28, 276–284. [Google Scholar] [CrossRef] [PubMed]
- Dąbrowska-Bender, M.; Milewska, M.; Gołąbek, A.; Duda-Zalewska, A.; Staniszewska, A.J. The impact of ischemic cerebral stroke on the quality of life of patients based on clinical, social, and psychoemotional factors. Stroke Cerebrovasc. Dis. 2017, 26, 101–107. [Google Scholar] [CrossRef]
- Skoglund, E.; Westerlind, E.; Persson, H.C.; Sunnerhagen, K.S. Self-perceived impact of stroke: A longitudinal comparison between one and five years post-stroke. J. Rehabil. Med. 2019, 51, 660–664. [Google Scholar] [CrossRef] [Green Version]
- Davis, C.M.; Fairbanks, S.L.; Alkayed, N.J. Mechanism of the sex difference in endothelial dysfunction after stroke. Transl. Stroke Res. 2013, 4, 381–389. [Google Scholar] [CrossRef]
- Shu, S.; Pei, L.; Lu, Y. Promising targets of cell death signaling of NR2B receptor subunit in stroke pathogenesis. Regen. Med. Res. 2014, 2, 8. [Google Scholar] [CrossRef] [Green Version]
- Szczuko, M.; Kotlęga, D.; Palma, J.; Zembroń-Łacny, A.; Tylutka, A.; Gołąb-Janowska, M.; Drozd, A. Lipoxins, RevD1 and 9, 13 HODE as the most important derivatives after an early incident of ischemic stroke. Sci. Rep. 2020, 10, 12849. [Google Scholar] [CrossRef]
- Kotlega, D.; Zembron-Lacny, A.; Golab-Janowska, M.; Nowacki, P.; Szczuko, M. The association of free fatty acids and eicosanoids with the severity of depressive symptoms in stroke patients. Int. J. Mol. Sci. 2020, 21, 5220. [Google Scholar] [CrossRef]
- Sakakibara, B.; Kim, A.; Eng, J. A systematic review and meta-analysis on self-management for improving risk factor control in stroke patients. Int. J. Behav. Med. 2017, 24, 42–53. [Google Scholar] [CrossRef] [Green Version]
- Kotlęga, D.; Gołąb-Janowska, M.; Meller, A.; Pawlukowska, W.; Nowacki, P. Detection of stroke risk factors over the decade in the polish population of ischemic stroke patients. Adv. Psychiatry Neurol. Postępy Psychiatrii i Neurologii 2019, 28, 83–87. [Google Scholar] [CrossRef]
- Kariasa, I.M.; Nurachmah, E.; Setyowati, S.; Koestoer, R.A. Analysis of participants’ characteristics and risk factors for stroke recurrence. Enferm. Clin. 2019, 29, 286–290. [Google Scholar] [CrossRef]
- Kernan, W.; Ovbiagele, B.; Black, H.; Bravata, D.; Chimowitz, M.; Ezekowitz, M.; Fang, M.C.; Fisher, M.; Furie, K.L.; Heck, D.V.; et al. Guidelines for prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014, 45, 2160–2236. [Google Scholar] [CrossRef]
- Kotlęga, D.; Ciećwież, S.; Turowska-Kowalska, J.; Nowacki, P. Pathogenetic justification of statin use in ischaemic stroke prevention according to inflammatory theory in development of atherosclerosis. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. Neurol. Neurochir. Polska 2012, 46, 176–183. [Google Scholar] [CrossRef] [PubMed]
- Goldstein, L.B.; Bushnell, C.D.; Adams, R.J.; Appel, L.J.; Braun, L.T.; Chaturvedi, S.; Creager, M.A.; Culebras, A.; Eckel, R.H.; Hart, R.G.; et al. Guidelines for the primary prevention of stroke. Stroke 2011, 42, 517–584. [Google Scholar] [CrossRef] [PubMed]
- Sahlin, C.; Sandberg, O.; Gustafson, Y.; Bucht, G.; Carlberg, B.; Stenlund, H.; Franklin, G.A. Obstructiove sleep apnea is a risk factor for death in patients with stroke: A 10-year follow-up. Arch. Intern. Med. 2008, 168, 297–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kernan, W.; Inzucchi, S.; Sawan, C.; Macko, R.; Furie, K. Obesity: A stubbornly obvious target prevention. Stroke 2013, 44, 278–286. [Google Scholar] [CrossRef]
- Vemmos, K.; Ntaios, G.; Spengos, K.; Savvari, P.; Vemmou, A.; Pappa, T.; Manios, E.D.; Georgiopoulos, G.; Alevizaki, M. Association between obesity and mortality after acute first-ever stroke. Stroke 2011, 42, 30–36. [Google Scholar] [CrossRef] [Green Version]
- Ovbiagele, B.; Bath, P.M.; Cotton, D.; Vinisko, R.; Diener, H.-C. Obesity and recurrent vascular risk after a recent ischemic stroke. Stroke 2011, 42, 3397–3402. [Google Scholar] [CrossRef]
- Haley, M.J.; Lawrence, C.B. Obesity and stroke: Can we translate from rodents to patients? Br. J. Pharmacol. 2016, 36, 2007–2021. [Google Scholar] [CrossRef]
- Anrather, J.; Iadecola, C. Inflammation and stroke: An overview. Neurotherapeutics 2016, 13, 661–670. [Google Scholar] [CrossRef]
- Jackman, K.; Iadecola, C. Neurovascular regulation in the ischemic brain. Antioxid. Redox Signal. 2015, 22, 149–160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Petrovic-Djergovic, D.; Goonewardena, S.N.; Pinsky, D.J. Inflammatory disequilibrium in stroke. Circ. Res. 2016, 119, 142–158. [Google Scholar] [CrossRef] [Green Version]
- Chapman, K.Z.; Dale, V.Q.; Dénes, Á.; Bennett, G.; Rothwell, N.J.; Allan, S.M.; McColl, B.W. A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. Br. J. Pharmacol. 2009, 29, 1764–1768. [Google Scholar] [CrossRef] [Green Version]
- Kes, V.B.; Simundic, A.-M.; Nikolac, N.; Topic, E.; Demarin, V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin. Biochem. 2008, 41, 1330–1334. [Google Scholar] [CrossRef]
- Zhao, L.; Funk, C.D.; Zhao, L.; Funk, C.D. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc. Med. 2004, 14, 191–195. [Google Scholar] [CrossRef]
- Hampel, J.K.; Brownrigg, L.M.; Vignarajah, D.; Croft, K.D.; Dharmarajan, A.M.; Bentel, J.M.; Puddey, I.B.; Yeap, B.B. Differential modulation of cell cycle, apoptosis and PPARγ2 gene expression by PPARγ agonists ciglitazone and 9-hydroxyoctadecadienoic acid in monocytic cells. Prostaglandins Leukot. Essent. Fat. Acids 2006, 74, 283–293. [Google Scholar] [CrossRef]
- Limor, R.; Sharon, O.; Knoll, E.; Many, A.; Weisinger, G.; Stern, N. Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor -2 expression in human vascular smooth muscle cells. Am. J. Hypertens. 2008, 21, 219–223. [Google Scholar] [CrossRef] [Green Version]
- Simonetto, M.; Infante, M.; Sacco, R.L.; Rundek, T.; Della-Morte, D. A novel anti-inflammatory role of omega-3 PUFAs in prevention and treatment of atherosclerosis and vascular cognitive impairment and dementia. Nutrients 2019, 11, 2279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carracedo, M.; Artiach, G.; Arnardottir, H.; Bäck, M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin. Immunopathol. 2019, 41, 757–766. [Google Scholar] [CrossRef] [Green Version]
- Viola, J.; Lemnitzer, P.; Jansen, Y.; Csaba, G.; Winter, C.; Neideck, C.; Silvestre-Roig, C.; Dittmar, G.; Döring, Y.; Drechsler, M.; et al. Resolving lipid mediatrs maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ. Res. 2016, 119, 1030–1038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bäck, M.; Hansson, G.K. Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation. FASEB J. 2019, 33, 1536–1539. [Google Scholar] [CrossRef] [PubMed]
- Saini, R.K.; Keum, Y.-S. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance—A review. Life Sci. 2018, 203, 255–267. [Google Scholar] [CrossRef] [PubMed]
- Brenna, J.; Salem, N.; Sinclair, A.J.; Cunnane, S.C. α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fat Acids 2009, 80, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Williams, C.; Burdge, G. Long-chain n-3 PUFA: Plant v. marine sources. Proc. Nutr. Soc. 2006, 65, 42–50. [Google Scholar] [CrossRef] [Green Version]
- Calder, P.C. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem. Soc. Trans. 2017, 45, 1105–1115. [Google Scholar] [CrossRef] [Green Version]
- Serhan, C.; Hong, S.; Gronert, K.; Colgan, S.; Devchand, P.; Mirick, G.; Moussignac, R.-L. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196, 1025–1037. [Google Scholar] [CrossRef] [Green Version]
- Nowak, J.Z. Anti-inflammatory pro-resolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Postępy Hig. Med. Dosw. 2010, 64, 115–132. [Google Scholar]
- Duvall, M.G.; Levy, B.D. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. Eur. J. Pharmacol. 2016, 785, 144–155. [Google Scholar] [CrossRef] [Green Version]
- Lambertsen, K.L.; Biber, K.; Finsen, B. Inflammatory cytokines in experimental and human stroke. Br. J. Pharmacol. 2012, 32, 1677–1698. [Google Scholar] [CrossRef] [Green Version]
- Bannenberg, G.; Serhan, C. Pro-resolving lipid mediators in the inflammatory response: An update. Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2010, 1801, 1260–1273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xie, G.; Myint, P.K.; Zaman, M.J.S.; Li, Y.; Zhao, L.; Shi, P.; Ren, F.; Wu, Y. Relationship of serum interleukin-10 and its genetic variations with ischemic stroke in a chinese general population. PLoS ONE 2013, 8, e74126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arponen, O.; Muuronen, A.; Taina, M.; Sipola, P.; Hedman, M.; Jäkälä, P.; Vanninen, R.; Pulkki, K.; Mustonen, P. Acute phase IL-10 plasma concentration associates with the high risk sources of cardiogenic stroke. PLoS ONE 2015, 10, e0120910. [Google Scholar] [CrossRef] [PubMed]
- Oh, S.F.; Dona, M.; Fredman, G.; Krishnamoorthy, S.; Irimia, D.; Serhan, C.N. Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 2012, 188, 4527–4534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jenny, N.; Callas, P.; Judd, S.; McClure, L.; Kissela, B.; Zakai, N.; Cuchman, M. Inflammatory cytokines and schemic stroke risk: The REGARDS cohort. Neurology 2019, 92, e2375–e2384. [Google Scholar] [CrossRef]
- Cherpokova, D.; Jouvene, C.C.; Libreros, S.; DeRoo, E.P.; Chu, L.; De La Rosa, X.; Norris, P.C.; Wagner, D.D.; Serhan, C.N. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood 2019, 134, 1458–1468. [Google Scholar] [CrossRef] [PubMed]
- Pirault, J.; Bäck, M. Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front Pharmacol. 2018, 9, 1273. [Google Scholar] [CrossRef] [PubMed]
- Elajami, T.K.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N.; Welty, F.K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016, 30, 2792–2801. [Google Scholar] [CrossRef] [Green Version]
- Fredman, G.; Spite, M. Specialized pro-resolving mediators in cardiovascular diseases. Mol. Asp. Med. 2017, 58, 65–71. [Google Scholar] [CrossRef]
- Doran, A.C.; Meller, N.; McNamara, C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arter. Thromb. Vasc. Biol. 2008, 28, 812–819. [Google Scholar] [CrossRef] [Green Version]
- Karagiannis, G.; Weile, J.; Bader, G.; Minta, J. Integrative pathway dissection of molecular mechanisms od moxLDL-induced vascular muscle phenotype transformation. BMC Cardiovasc. Disord. 2013, 13, 4. [Google Scholar] [CrossRef] [Green Version]
- Arita, M.; Ohira, T.; Sun, Y.-P.; Elangovan, S.; Chiang, N.; Serhan, C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and chemr23 to regulate inflammation. J. Immunol. 2007, 178, 3912–3917. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laguna-Fernandez, A.; Checa, A.; Carracedo, M.; Artiach, G.; Petri, M.; Baumgartner, R.; Forteza, M.J.; Jiang, X.; Andonova, T.; Waler, M.E.; et al. ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation 2018, 138, 1693–1705. [Google Scholar] [CrossRef] [PubMed]
- Zuo, G.; Zhang, D.; Mu, R.; Shen, H.; Li, X.; Wang, Z.; Li, H.; Chen, G. Resolvin D2 protects against cerebral ischemia/reperfusion injury in rats. Mol. Brain 2018, 11, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Bäck, M. Omega-3 fatty acids in atherosclerosis and coronary artery disease. Futur. Sci. OA 2017, 3. [Google Scholar] [CrossRef] [Green Version]
- Panigrahy, D.; Gartung, A.; Yang, J.; Yang, H.; Gilligan, M.M.; Sulciner, M.L.; Bhasin, S.S.; Bielenberg, D.R.; Chang, J.; Schmidt, B.A.; et al. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J. Clin. Investig. 2019, 129, 2964–2979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dong, X.; Gao, J.; Zhang, C.Y.; Hayworth, C.; Frank, M.; Wang, Z. Neutrophil membrane-derived nanovesicles alleviate inflammation to protect mouse brain injury from ischemic stroke. ACS Nano 2019, 13, 1272–1283. [Google Scholar] [CrossRef] [PubMed]
- Chiang, N.; Dalli, J.; Colas, R.A.; Serhan, C.N. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J. Exp. Med. 2015, 212, 1203–1217. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.-S.; Maruyama, C.L.; Easley, J.T.; Trump, B.G.; Baker, O.J. AT-RvD1 promotes resolution of inflammation in NOD/ShiLtJ mice. Sci. Rep. 2017, 7. [Google Scholar] [CrossRef]
- Bacarin, C.C.; Mori, M.A.; Ferreira, E.D.F.; Romanini, C.V.; De Oliveira, R.M.W.; Milani, H. Fish oil provides robust and sustained memory recovery after cerebral ischemia: Influence of treatment regimen. Physiol. Behav. 2013, 119, 61–71. [Google Scholar] [CrossRef]
- Xu, M.; Tan, B.; Zhou, W.; Wei, T.; Lai, W.; Tan, J.-W.; Dong, J. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci. Ther. 2013, 19, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Murray, P.J.; Wynn, T.A. Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 2011, 89, 557–563. [Google Scholar] [CrossRef] [PubMed]
- Nazimek, K.; Bryniarski, K. The biological activity of macrophages in health and disease. Postępy Hig. Med. Dosw. 2012, 66, 507–520. [Google Scholar] [CrossRef] [PubMed]
- Akagi, D.; Chen, M.; Toy, R.; Chatterjee, A.; Conte, M.S. Systemic delivery of proresolving lipid mediators resolvin D 2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015, 29, 2504–2513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eitos, E.; Rius, B.; Gonzalez-Periz, A.; Lopez-Vicario, C.; Moran-Salvador, E.; Martinez-Clemente, M.; Arroyo, V.; Claria, J. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization towar dan M2-like phenotype. J. Immunol. 2011, 187, 5408–5418. [Google Scholar]
- Hsiao, H.-M.; Sapinoro, R.E.; Thatcher, T.H.; Croasdell, A.; Levy, E.P.; Fulton, R.A.; Olsen, K.C.; Pollock, S.J.; Serhan, C.N.; Phipps, R.P.; et al. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE 2013, 8, e58258. [Google Scholar] [CrossRef] [Green Version]
- Salic, K.; Morrison, M.C.; Verschuren, L.; Wielinga, P.Y.; Wu, L.; Kleemann, R.; Gjorstrup, P.; Kooistra, T. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 2016, 250, 158–165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krashia, P.; Cordella, A.; Nobili, A.; La Barbera, L.; Federici, M.; Leuti, A.; Campanelli, F.; Natale, G.; Marino, G.; Calabrese, V.; et al. Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease. Nat. Commun. 2019, 10, 1–19. [Google Scholar] [CrossRef] [Green Version]
- Hasturk, H.; Abdallah, R.; Kantarci, A.; Nguyen, D.; Giordano, N.; Hamilton, J.; Van Dyke, T.E. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arter. Thromb. Vasc. Biol. 2015, 35, 1123–1133. [Google Scholar] [CrossRef] [Green Version]
- Capó, X.; Martorell, M.; Busquets-Cortés, C.; Tejada, S.; Tur, J.A.; Pons, A.; Sureda, A. Resolvins as proresolving inflammatory mediators in cardiovascular disease. Eur. J. Med. Chem. 2018, 153, 123–130. [Google Scholar] [CrossRef]
- Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090–1098. [Google Scholar] [CrossRef]
- Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 2019, 380, 11–22. [Google Scholar] [CrossRef] [PubMed]
- Risk and Prevention Study Collaborative Group; Roncaglioni, M.C.; Tombesi, M.; Avanzini, F.; Barlera, S.; Caimi, V.; Longoni, P.; Marzona, I.; Milani, V.; Silletta, M.G.; et al. n–3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 2013, 368, 1800–1808. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manson, J.E.; Cook, N.R.; Lee, I.-M.; Christen, W.; Bassuk, S.S.; Mora, S.; Gibson, H.; Albert, C.M.; Gordon, D.; Copeland, T.; et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N. Engl. J. Med. 2019, 380, 23–32. [Google Scholar] [CrossRef]
Omega-3 | Resolvin Subtypes | Corresponding Receptors | Localisation | Function |
---|---|---|---|---|
EPA | RvE1 | ChemR23 (ERV, CMKLR1) | Chemerin receptor 23 is expressed on NK cells, ILCs, macrophages, dendritic cells, and epithelial cells | stimulation of phagocytosis decrease in the level of proinflammatory cytokines |
BLT1 | ||||
RvE2 | BLT1 | Leukotriene LTB4 is expressed on human neutrophils, eosinophils, monocytes, macrophages, mast cells, dendritic cells, and T cells | reduction in neutrophil mobilization | |
DHA- | RvD1 | ALX/FPR2 | Expression on neutrophils, macrophages, monocytes, macrophages, and T cells | increase of phagocytosis prevention of the differentiation of T-lymphocytes towards Th1 and Th12, promotion of regulatory cell (Tr) formation |
DRV1/GPR32 | The G-23 protein coupled receptor is expressed on human neutrophils, lymphocytes, macrophages, and monocytes, as well as vascular tissues | |||
RvD2 | DRV1/GPR32 | development of CD8a lymphocytes in the small intestine migration ability of immune cells recruitment of granulocytes decrease in blood pressure | ||
DRV2/GPR18 | The G-18 protein coupled receptor is expressed on human and murine neutrophils, monocytes, and macrophages | |||
RvD3 | DRV1/GPR32 | The G-23 protein coupled receptor is expressed on human neutrophils, lymphocytes, macrophages, and monocytes, as well as vascular tissues | promotion of macrophage phagocytosis | |
RvD4 | G protein-coupled receptors: no data | inhibition of metastases and induced T cell responses | ||
RvD5 | DRV1/GPR32 | The G-23 protein coupled receptor is expressed on human neutrophils, lymphocytes, macrophages, and monocytes, as well as vascular tissues | expression of macrophages increase of phagocytosis. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tułowiecka, N.; Kotlęga, D.; Prowans, P.; Szczuko, M. The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke. Int. J. Mol. Sci. 2020, 21, 7628. https://doi.org/10.3390/ijms21207628
Tułowiecka N, Kotlęga D, Prowans P, Szczuko M. The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke. International Journal of Molecular Sciences. 2020; 21(20):7628. https://doi.org/10.3390/ijms21207628
Chicago/Turabian StyleTułowiecka, Nikola, Dariusz Kotlęga, Piotr Prowans, and Małgorzata Szczuko. 2020. "The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke" International Journal of Molecular Sciences 21, no. 20: 7628. https://doi.org/10.3390/ijms21207628